Consolidation  ||| S:0 E:14 ||| NN
therapy  ||| S:14 E:22 ||| NN
in  ||| S:22 E:25 ||| IN
ovarian  ||| S:25 E:33 ||| JJ
cancer ||| S:33 E:39 ||| NN
:  ||| S:39 E:41 ||| :
a  ||| S:41 E:43 ||| DT
clinical  ||| S:43 E:52 ||| JJ
update  ||| S:52 E:59 ||| NN
To  ||| S:59 E:62 ||| TO
evaluate  ||| S:62 E:71 ||| VB
current  ||| S:71 E:79 ||| JJ
strategies  ||| S:79 E:90 ||| NNS
under  ||| S:90 E:96 ||| IN
investigation  ||| S:96 E:110 ||| NN
for  ||| S:110 E:114 ||| IN
use  ||| S:114 E:118 ||| NN
as  ||| S:118 E:121 ||| IN
consolidation  ||| S:121 E:135 ||| NN
or  ||| S:135 E:138 ||| CC
maintenance  ||| S:138 E:150 ||| NN
treatment  ||| S:150 E:160 ||| NN
in  ||| S:160 E:163 ||| IN
patients  ||| S:163 E:172 ||| NNS
with  ||| S:172 E:177 ||| IN
ovarian  ||| S:177 E:185 ||| JJ
cancer ||| S:185 E:191 ||| NN
.  ||| S:191 E:193 ||| .
Patients  ||| S:193 E:202 ||| NNS
with  ||| S:202 E:207 ||| IN
epithelial  ||| S:207 E:218 ||| JJ
ovarian  ||| S:218 E:226 ||| JJ
cancer  ||| S:226 E:233 ||| NN
often  ||| S:233 E:239 ||| RB
enter  ||| S:239 E:245 ||| VB
a  ||| S:245 E:247 ||| DT
complete  ||| S:247 E:256 ||| JJ
remission  ||| S:256 E:266 ||| NN
after  ||| S:266 E:272 ||| IN
primary  ||| S:272 E:280 ||| JJ
treatment ||| S:280 E:289 ||| NN
.  ||| S:289 E:291 ||| .
Many  ||| S:291 E:296 ||| JJ
relapse ||| S:296 E:303 ||| NN
,  ||| S:303 E:305 ||| ,
unfortunately ||| S:305 E:318 ||| RB
,  ||| S:318 E:320 ||| ,
but  ||| S:320 E:324 ||| CC
some  ||| S:324 E:329 ||| DT
can  ||| S:329 E:333 ||| MD
return  ||| S:333 E:340 ||| VB
to  ||| S:340 E:343 ||| TO
remission  ||| S:343 E:353 ||| VB
after  ||| S:353 E:359 ||| IN
additional  ||| S:359 E:370 ||| JJ
treatment ||| S:370 E:379 ||| NN
.  ||| S:379 E:381 ||| .
Outcomes  ||| S:381 E:390 ||| NNP
can  ||| S:390 E:394 ||| MD
be  ||| S:394 E:397 ||| VB
improved  ||| S:397 E:406 ||| VBN
by  ||| S:406 E:409 ||| IN
applying  ||| S:409 E:418 ||| VBG
effective  ||| S:418 E:428 ||| JJ
consolidation  ||| S:428 E:442 ||| NN
or  ||| S:442 E:445 ||| CC
maintenance  ||| S:445 E:457 ||| NN
approaches  ||| S:457 E:468 ||| NNS
to  ||| S:468 E:471 ||| TO
patients  ||| S:471 E:480 ||| NNS
in  ||| S:480 E:483 ||| IN
a  ||| S:483 E:485 ||| DT
complete  ||| S:485 E:494 ||| JJ
primary  ||| S:494 E:502 ||| JJ
or  ||| S:502 E:505 ||| CC
subsequent  ||| S:505 E:516 ||| JJ
remission ||| S:516 E:525 ||| NN
.  ||| S:525 E:527 ||| .
A  ||| S:527 E:529 ||| DT
selective  ||| S:529 E:539 ||| JJ
review  ||| S:539 E:546 ||| NN
of  ||| S:546 E:549 ||| IN
the  ||| S:549 E:553 ||| DT
literature  ||| S:553 E:564 ||| NN
is  ||| S:564 E:567 ||| VBZ
undertaken  ||| S:567 E:578 ||| VBN
to  ||| S:578 E:581 ||| TO
consider  ||| S:581 E:590 ||| VB
strategies  ||| S:590 E:601 ||| NNS
that  ||| S:601 E:606 ||| WDT
are  ||| S:606 E:610 ||| VBP
being  ||| S:610 E:616 ||| VBG
or  ||| S:616 E:619 ||| CC
will  ||| S:619 E:624 ||| MD
likely  ||| S:624 E:631 ||| RB
be  ||| S:631 E:634 ||| VB
evaluated  ||| S:634 E:644 ||| VBN
in  ||| S:644 E:647 ||| IN
randomized  ||| S:647 E:658 ||| JJ
trials  ||| S:658 E:665 ||| NNS
while  ||| S:665 E:671 ||| IN
we  ||| S:671 E:674 ||| PRP
assess  ||| S:674 E:681 ||| VBP
whether  ||| S:681 E:689 ||| IN
consolidation  ||| S:689 E:703 ||| NN
or  ||| S:703 E:706 ||| CC
maintenance  ||| S:706 E:718 ||| NN
will  ||| S:718 E:723 ||| MD
have  ||| S:723 E:728 ||| VB
a  ||| S:728 E:730 ||| DT
place  ||| S:730 E:736 ||| NN
in  ||| S:736 E:739 ||| IN
the  ||| S:739 E:743 ||| DT
treatment  ||| S:743 E:753 ||| NN
of  ||| S:753 E:756 ||| IN
patients  ||| S:756 E:765 ||| NNS
with  ||| S:765 E:770 ||| IN
ovarian  ||| S:770 E:778 ||| JJ
cancer ||| S:778 E:784 ||| NN
.  ||| S:784 E:786 ||| .
The  ||| S:786 E:790 ||| DT
application  ||| S:790 E:802 ||| NN
of  ||| S:802 E:805 ||| IN
extended  ||| S:805 E:814 ||| JJ
standard  ||| S:814 E:823 ||| JJ
cytotoxic  ||| S:823 E:833 ||| JJ
agents  ||| S:833 E:840 ||| NNS
has  ||| S:840 E:844 ||| VBZ
been  ||| S:844 E:849 ||| VBN
generally  ||| S:849 E:859 ||| RB
disappointing ||| S:859 E:872 ||| JJ
,  ||| S:872 E:874 ||| ,
and  ||| S:874 E:878 ||| CC
no  ||| S:878 E:881 ||| DT
strategy  ||| S:881 E:890 ||| NN
applied  ||| S:890 E:898 ||| VBN
in  ||| S:898 E:901 ||| IN
the  ||| S:901 E:905 ||| DT
first  ||| S:905 E:911 ||| JJ
remission  ||| S:911 E:921 ||| JJ
setting  ||| S:921 E:929 ||| NN
has  ||| S:929 E:933 ||| VBZ
prolonged  ||| S:933 E:943 ||| VBN
overall  ||| S:943 E:951 ||| JJ
survival ||| S:951 E:959 ||| NN
.  ||| S:959 E:961 ||| .
As  ||| S:961 E:964 ||| IN
treatment  ||| S:964 E:974 ||| NN
options  ||| S:974 E:982 ||| NNS
move  ||| S:982 E:987 ||| VBP
beyond  ||| S:987 E:994 ||| IN
classic  ||| S:994 E:1002 ||| JJ
chemotherapy  ||| S:1002 E:1015 ||| NN
to  ||| S:1015 E:1018 ||| TO
novel  ||| S:1018 E:1024 ||| NN
hormones ||| S:1024 E:1032 ||| NNS
,  ||| S:1032 E:1034 ||| ,
immune  ||| S:1034 E:1041 ||| JJ
interventions ||| S:1041 E:1054 ||| NNS
,  ||| S:1054 E:1056 ||| ,
and  ||| S:1056 E:1060 ||| CC
biologic  ||| S:1060 E:1069 ||| JJ
agents ||| S:1069 E:1075 ||| NNS
,  ||| S:1075 E:1077 ||| ,
the  ||| S:1077 E:1081 ||| DT
consolidation  ||| S:1081 E:1095 ||| NN
strategy  ||| S:1095 E:1104 ||| NN
is  ||| S:1104 E:1107 ||| VBZ
regaining  ||| S:1107 E:1117 ||| VBG
interest ||| S:1117 E:1125 ||| NN
.  ||| S:1125 E:1127 ||| .
This  ||| S:1127 E:1132 ||| DT
is  ||| S:1132 E:1135 ||| VBZ
particularly  ||| S:1135 E:1148 ||| RB
attractive  ||| S:1148 E:1159 ||| JJ
in  ||| S:1159 E:1162 ||| IN
that  ||| S:1162 E:1167 ||| DT
many  ||| S:1167 E:1172 ||| JJ
of  ||| S:1172 E:1175 ||| IN
these  ||| S:1175 E:1181 ||| DT
agents  ||| S:1181 E:1188 ||| NNS
have  ||| S:1188 E:1193 ||| VBP
stable  ||| S:1193 E:1200 ||| JJ
disease  ||| S:1200 E:1208 ||| NN
as  ||| S:1208 E:1211 ||| IN
best  ||| S:1211 E:1216 ||| JJS
outcome ||| S:1216 E:1223 ||| NN
,  ||| S:1223 E:1225 ||| ,
and  ||| S:1225 E:1229 ||| CC
this  ||| S:1229 E:1234 ||| DT
is  ||| S:1234 E:1237 ||| VBZ
most  ||| S:1237 E:1242 ||| RBS
appropriate  ||| S:1242 E:1254 ||| JJ
to  ||| S:1254 E:1257 ||| TO
evaluate  ||| S:1257 E:1266 ||| VB
in  ||| S:1266 E:1269 ||| IN
patients  ||| S:1269 E:1278 ||| NNS
with  ||| S:1278 E:1283 ||| IN
minimal  ||| S:1283 E:1291 ||| JJ
volume  ||| S:1291 E:1298 ||| NN
disease ||| S:1298 E:1305 ||| NN
.  ||| S:1305 E:1307 ||| .
A  ||| S:1307 E:1309 ||| DT
consideration  ||| S:1309 E:1323 ||| NN
of  ||| S:1323 E:1326 ||| IN
toxicity  ||| S:1326 E:1335 ||| NN
is  ||| S:1335 E:1338 ||| VBZ
paramount ||| S:1338 E:1347 ||| VBN
,  ||| S:1347 E:1349 ||| ,
and  ||| S:1349 E:1353 ||| CC
any  ||| S:1353 E:1357 ||| DT
strategy  ||| S:1357 E:1366 ||| NN
to  ||| S:1366 E:1369 ||| TO
be  ||| S:1369 E:1372 ||| VB
considered  ||| S:1372 E:1383 ||| VBN
in  ||| S:1383 E:1386 ||| IN
an  ||| S:1386 E:1389 ||| DT
otherwise  ||| S:1389 E:1399 ||| RB
asymptomatic  ||| S:1399 E:1412 ||| JJ
patient  ||| S:1412 E:1420 ||| NN
in  ||| S:1420 E:1423 ||| IN
remission  ||| S:1423 E:1433 ||| NNS
must  ||| S:1433 E:1438 ||| MD
be  ||| S:1438 E:1441 ||| VB
well  ||| S:1441 E:1446 ||| RB
tolerated ||| S:1446 E:1455 ||| VBN
.  ||| S:1455 E:1457 ||| .
In  ||| S:1457 E:1460 ||| IN
addition ||| S:1460 E:1468 ||| NN
,  ||| S:1468 E:1470 ||| ,
patients  ||| S:1470 E:1479 ||| NNS
in  ||| S:1479 E:1482 ||| IN
second  ||| S:1482 E:1489 ||| JJ
or  ||| S:1489 E:1492 ||| CC
third  ||| S:1492 E:1498 ||| JJ
complete  ||| S:1498 E:1507 ||| JJ
remission  ||| S:1507 E:1517 ||| NNS
are  ||| S:1517 E:1521 ||| VBP
also  ||| S:1521 E:1526 ||| RB
being  ||| S:1526 E:1532 ||| VBG
considered  ||| S:1532 E:1543 ||| VBN
as  ||| S:1543 E:1546 ||| IN
an  ||| S:1546 E:1549 ||| DT
appropriate  ||| S:1549 E:1561 ||| JJ
group  ||| S:1561 E:1567 ||| NN
in  ||| S:1567 E:1570 ||| IN
which  ||| S:1570 E:1576 ||| WDT
to  ||| S:1576 E:1579 ||| TO
evaluate  ||| S:1579 E:1588 ||| VB
new  ||| S:1588 E:1592 ||| JJ
agents ||| S:1592 E:1598 ||| NNS
.  ||| S:1598 E:1600 ||| .
Numerous  ||| S:1600 E:1609 ||| JJ
other  ||| S:1609 E:1615 ||| JJ
phase  ||| S:1615 E:1621 ||| NN
2  ||| S:1621 E:1623 ||| CD
trials  ||| S:1623 E:1630 ||| NNS
with  ||| S:1630 E:1635 ||| IN
novel  ||| S:1635 E:1641 ||| NN
agents  ||| S:1641 E:1648 ||| NNS
not  ||| S:1648 E:1652 ||| RB
considered  ||| S:1652 E:1663 ||| VBN
here  ||| S:1663 E:1668 ||| RB
are  ||| S:1668 E:1672 ||| VBP
underway ||| S:1672 E:1680 ||| VBN
,  ||| S:1680 E:1682 ||| ,
and  ||| S:1682 E:1686 ||| CC
it  ||| S:1686 E:1689 ||| PRP
is  ||| S:1689 E:1692 ||| VBZ
to  ||| S:1692 E:1695 ||| TO
be  ||| S:1695 E:1698 ||| VB
hoped  ||| S:1698 E:1704 ||| VBN
that  ||| S:1704 E:1709 ||| IN
some  ||| S:1709 E:1714 ||| DT
will  ||| S:1714 E:1719 ||| MD
emerge  ||| S:1719 E:1726 ||| VB
as  ||| S:1726 E:1729 ||| IN
contenders  ||| S:1729 E:1740 ||| NNS
for  ||| S:1740 E:1744 ||| IN
randomized  ||| S:1744 E:1755 ||| JJ
trials ||| S:1755 E:1761 ||| NNS
.  ||| S:1761 E:1763 ||| .
Participation  ||| S:1763 E:1777 ||| NN
in  ||| S:1777 E:1780 ||| IN
these  ||| S:1780 E:1786 ||| DT
trials  ||| S:1786 E:1793 ||| NN
remains  ||| S:1793 E:1801 ||| VBZ
a  ||| S:1801 E:1803 ||| DT
priority  ||| S:1803 E:1812 ||| NN
for  ||| S:1812 E:1816 ||| IN
patients  ||| S:1816 E:1825 ||| NNS
who  ||| S:1825 E:1829 ||| WP
otherwise  ||| S:1829 E:1839 ||| RB
must  ||| S:1839 E:1844 ||| MD
pursue  ||| S:1844 E:1851 ||| VB
a  ||| S:1851 E:1853 ||| DT
difficult  ||| S:1853 E:1863 ||| JJ
watch-and-wait  ||| S:1863 E:1878 ||| JJ
strategy ||| S:1878 E:1886 ||| NN
.  ||| S:1886 E:1888 ||| .
